Sage Therapeutics Surges 12.2 percent Is This an Indication of Further Gains?
ASND Stock | USD 140.31 1.52 1.10% |
About 57% of all Ascendis Pharma's shareholders are looking to take a long position. The analysis of the overall investor sentiment regarding Ascendis Pharma AS suggests that some traders are interested. The current market sentiment, together with Ascendis Pharma's historical and current headlines, can help investors time the market. In addition, many technical investors use Ascendis Pharma AS stock news signals to limit their universe of possible portfolio assets.
Ascendis |
Sage Therapeutics witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesnt suggest further strength down the road.
Read at zacks.com
Ascendis Pharma Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Ascendis Pharma can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Ascendis Pharma Fundamental Analysis
We analyze Ascendis Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ascendis Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ascendis Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Return On Asset
Return On Asset Comparative Analysis
Ascendis Pharma is currently under evaluation in return on asset category among its peers. Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Ascendis Pharma AS Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Ascendis Pharma stock to make a market-neutral strategy. Peer analysis of Ascendis Pharma could also be used in its relative valuation, which is a method of valuing Ascendis Pharma by comparing valuation metrics with similar companies.
Peers
Ascendis Pharma Related Equities
PLRX | Pliant Therapeutics | 4.00 | ||||
VTYX | Ventyx Biosciences | 2.64 | ||||
REPL | Replimune | 2.32 | ||||
ACLX | Arcellx | 1.86 | ||||
DAWN | Day One | 1.82 | ||||
AMLX | Amylyx Pharmaceuticals | 1.75 | ||||
BGNE | BeiGene | 1.68 | ||||
BPMC | Blueprint Medicines | 1.28 | ||||
AKRO | Akero Therapeutics | 1.16 | ||||
UTHR | United Therapeutics | 0.90 | ||||
ETNB | 89bio | 0.88 | ||||
MDGL | Madrigal Pharmaceuticals | 0.65 | ||||
CRNX | Crinetics Pharmaceuticals | 0.04 | ||||
STOK | Stoke Therapeutics | 0.71 | ||||
NUVL | Nuvalent | 0.71 | ||||
APLS | Apellis Pharmaceuticals | 1.08 |
Complementary Tools for Ascendis Stock analysis
When running Ascendis Pharma's price analysis, check to measure Ascendis Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ascendis Pharma is operating at the current time. Most of Ascendis Pharma's value examination focuses on studying past and present price action to predict the probability of Ascendis Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ascendis Pharma's price. Additionally, you may evaluate how the addition of Ascendis Pharma to your portfolios can decrease your overall portfolio volatility.
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |